[{"address1": "7 Times Square", "address2": "43rd Floor", "city": "New York", "state": "NY", "zip": "10036", "country": "United States", "phone": "929-999-4055", "website": "https://dianthustx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.", "fullTimeEmployees": 53, "auditRisk": 6, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1717200000, "maxAge": 86400, "priceHint": 2, "previousClose": 25.86, "open": 26.36, "dayLow": 24.38, "dayHigh": 26.5, "regularMarketPreviousClose": 25.86, "regularMarketOpen": 26.36, "regularMarketDayLow": 24.38, "regularMarketDayHigh": 26.5, "forwardPE": -10.051182, "volume": 989569, "regularMarketVolume": 989569, "averageVolume": 182685, "averageVolume10days": 351720, "averageDailyVolume10Day": 351720, "bid": 25.36, "ask": 25.72, "bidSize": 200, "askSize": 100, "marketCap": 749292736, "fiftyTwoWeekLow": 0.66, "fiftyTwoWeekHigh": 33.77, "priceToSalesTrailing12Months": 232.4109, "fiftyDayAverage": 23.742, "twoHundredDayAverage": 17.98495, "currency": "USD", "enterpriseValue": 372752928, "floatShares": 14450211, "sharesOutstanding": 29349500, "sharesShort": 2084001, "sharesShortPriorMonth": 1908350, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.071, "heldPercentInsiders": 0.088360004, "heldPercentInstitutions": 0.89129996, "shortRatio": 14.31, "shortPercentOfFloat": 0.1, "impliedSharesOutstanding": 29349500, "bookValue": 12.699, "priceToBook": 2.0103946, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -50214000, "trailingEps": -1.71, "forwardEps": -2.54, "enterpriseToRevenue": 115.618, "enterpriseToEbitda": -6.398, "52WeekChange": 35.471428, "SandP52WeekChange": 0.26238096, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "DNTH", "underlyingSymbol": "DNTH", "shortName": "Dianthus Therapeutics, Inc.", "longName": "Dianthus Therapeutics, Inc.", "firstTradeDateEpochUtc": 1529587800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "1c256785-fa9a-34f5-a846-6abff7f6272e", "messageBoardId": "finmb_631649032", "gmtOffSetMilliseconds": -14400000, "currentPrice": 25.53, "targetHighPrice": 84.0, "targetLowPrice": 38.0, "targetMeanPrice": 48.75, "targetMedianPrice": 44.5, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 8, "totalCash": 377036000, "totalCashPerShare": 12.846, "ebitda": -58260000, "totalDebt": 497000, "quickRatio": 42.182, "currentRatio": 42.519, "totalRevenue": 3224000, "debtToEquity": 0.133, "revenuePerShare": 0.284, "returnOnAssets": -0.16048001, "returnOnEquity": -0.2283, "freeCashflow": -25086376, "operatingCashflow": -41518000, "revenueGrowth": 0.836, "grossMargins": 1.0, "operatingMargins": -20.41648, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]